Verified in Collaboration with Retroscreen Virology Ltd.*1 of the UK
Sharp Announces the Effectiveness of High Concentrations of Plasmacluster Ions®*2 in London
The following is an overview of the announcement on the effectiveness of the technology for generating high concentrations of Plasmacluster Ions®*2 that was held on May 14, 2009, in London, UK.
Sharp Corporation, working in collaboration with Retroscreen Virology Ltd.*1 founded by Professor John S. Oxford of the University of London, has demonstrated that Plasmacluster Ion®*2 technology inactivate and eliminate the airborne, highly pathogenic H5N1 avian influenza virus by 99% in ten minutes at an ion concentration of approximately 7,000 ions/cm3 in a 1-m3 box.
Prof. John S. Oxford of the University of London announces the verified data
Kozo Takahashi, Executive Officer and Group General Manager of Health and Environment Systems Group
Executive Officer and Group General Manager of Health and Environment Systems Group, Kozo Takahashi, explains the orientation of Sharp's R&D.
The scene at the announcement
Prof. John S. Oxford of the University of London uses a mockup to explain how Plasmacluster Ions work against an airborne virus
- *1 The OECD (Organisation for Economic Co-operation and Development) Principles of GLP (Good Laboratory Practice) is a set of standards intended to ensure the generation of high-quality and reliable test data through periodic reviews of operational organization and management, test apparatus and materials, study designs, internal audit controls, quality assurance systems, test data, etc., at all test facilities. Re-certification is required every three years.
- *2 Plasmacluster and Plasmacluster Ions are trademarks of Sharp Corporation.